Profound Medical Corp. 8-K

What Happened
Profound Medical Corp. (PROF) filed a Form 8‑K on February 12, 2026, under Item 7.01 (Regulation FD Disclosure) to announce that INOVAIT — the Canadian national network for commercializing image‑guided therapy and AI — honored the company with the 2025–2026 Mount Logan Award recognizing the TULSA Procedure for prostate disease. The company furnished a press release dated February 12, 2026, as Exhibit 99.1 to the report.

Key Details

• Filing date: February 12, 2026 (Form 8‑K, Item 7.01 Regulation FD Disclosure).
• Award: INOVAIT’s 2025–2026 Mount Logan Award specifically recognizing the TULSA Procedure for prostate disease.
• Disclosure format: Press release furnished as Exhibit 99.1 to the Form 8‑K.
• Report signed by Rashed Dewan, Chief Financial Officer, on behalf of Profound Medical Corp.

Why It Matters
This disclosure highlights third‑party recognition of Profound’s TULSA Procedure, which can support commercial credibility and awareness for the company’s prostate‑disease treatment technology. For investors, awards and industry recognition can aid market adoption and partner interest, but the filing does not include financial results or material operational changes—it's an informational press release furnished under Regulation FD.